Symbols / APGE $90.68 -0.20% Apogee Therapeutics, Inc.
APGE Chart
About
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Market Cap | 6.76B | Enterprise Value | 5.52B | Income | -255.84M | Sales | — | Book/sh | 13.21 | Cash/sh | 10.61 |
| Dividend Yield | — | Payout | 0.00% | Employees | 261 | IPO | — | P/E | — | Forward P/E | -16.61 |
| PEG | — | P/S | — | P/B | 6.86 | P/C | — | EV/EBITDA | -19.43 | EV/Sales | — |
| Quick Ratio | 26.38 | Current Ratio | 26.57 | Debt/Eq | 0.98 | LT Debt/Eq | — | EPS (ttm) | -4.22 | EPS next Y | -5.46 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-11 | ROA | -21.11% | ROE | -31.57% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 61.11M | Shs Float | 52.93M | Short Float | 22.28% |
| Short Ratio | 7.44 | Short Interest | — | 52W High | 95.31 | 52W Low | 34.34 | Beta | 1.02 | Avg Volume | 979.56K |
| Volume | 427.44K | Target Price | $116.87 | Recom | Strong_buy | Prev Close | $90.86 | Price | $90.68 | Change | -0.20% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-30 | main | Mizuho | Outperform → Outperform | $110 |
| 2026-03-24 | main | Citigroup | Buy → Buy | $125 |
| 2026-03-24 | main | Canaccord Genuity | Buy → Buy | $130 |
| 2026-03-24 | main | Guggenheim | Buy → Buy | $160 |
| 2026-03-23 | reit | BTIG | Buy → Buy | $137 |
| 2026-03-18 | init | Truist Securities | — → Hold | $83 |
| 2026-03-16 | reit | BTIG | Buy → Buy | $137 |
| 2026-03-03 | main | RBC Capital | Sector Perform → Sector Perform | $82 |
| 2026-03-03 | main | Wedbush | Outperform → Outperform | $95 |
| 2026-01-22 | down | RBC Capital | Outperform → Sector Perform | $83 |
| 2026-01-07 | init | Wolfe Research | — → Peer Perform | — |
| 2026-01-06 | main | BTIG | Buy → Buy | $137 |
| 2026-01-05 | main | BTIG | Buy → Buy | $128 |
| 2025-12-17 | init | Stephens & Co. | — → Overweight | $95 |
| 2025-12-10 | init | Deutsche Bank | — → Buy | $103 |
| 2025-11-03 | init | Craig-Hallum | — → Buy | $109 |
| 2025-11-03 | main | RBC Capital | Outperform → Outperform | $70 |
| 2025-10-21 | init | Mizuho | — → Outperform | $105 |
| 2025-10-09 | reit | BTIG | Buy → Buy | $115 |
| 2025-09-25 | init | RBC Capital | — → Outperform | $60 |
- Apogee Thera (APGE) Stock Price Target | Q4 2025: Earnings Beat Estimates - Trending Volume Leaders - Xã Châu Thành hu, 23 Apr 2026 00
- Apogee Therapeutics (APGE) CEO exercises options, holds 1.14M shares - Stock Titan Mon, 20 Apr 2026 20
- APGE May 2026 50.000 call (APGE260515C00050000) Interactive Stock Chart - Yahoo Finance Mon, 20 Apr 2026 20
- APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN Fri, 17 Apr 2026 01
- APGE Stock Price and Chart — NASDAQ:APGE - TradingView ue, 24 Mar 2026 07
- APGE Earnings History & Surprises | EPS & Revenue Results | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill Fri, 17 Apr 2026 07
- Apogee Therapeutics (APGE) CMO sells shares worth $466,619 - Investing.com Fri, 03 Apr 2026 07
- $APGE stock is up 18% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Mar 2026 07
- Apogee Therapeutics (APGE) CFO sells 2,000 shares under 10b5-1 plan - Stock Titan Sat, 18 Apr 2026 00
- $APGE stock is down 12% today. Here's what we see in our data. | APGE Stock News - Quiver Quantitative Fri, 23 Jan 2026 08
- Biotech Apogee raises $403M after underwriters buy extra shares - Stock Titan hu, 26 Mar 2026 07
- End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations - Yahoo Finance Wed, 18 Feb 2026 08
- Apogee seeks $300M to fund clinical trials and manufacturing - Stock Titan Mon, 23 Mar 2026 07
- Here is Why Apogee Therapeutics (APGE) Appears Attractive - Yahoo Finance Mon, 16 Feb 2026 08
- Apogee Therapeutics (APGE) CEO sells 20,000 shares under Rule 10b5-1 plan - Stock Titan Fri, 10 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
285.60
+31.69%
|
216.87
+133.19%
|
93.00
+202.68%
|
30.73
|
| Research And Development |
|
214.71
+27.91%
|
167.87
+145.33%
|
68.42
+146.25%
|
27.79
|
| Selling General And Administration |
|
69.75
+42.34%
|
49.01
+99.38%
|
24.58
+735.74%
|
2.94
|
| General And Administrative Expense |
|
69.75
+42.34%
|
49.01
+99.38%
|
24.58
+735.74%
|
2.94
|
| Salaries And Wages |
|
50.64
+67.10%
|
30.30
+140.94%
|
12.58
+665.96%
|
1.64
|
| Other Gand A |
|
19.12
+2.22%
|
18.70
-23.91%
|
24.58
+1792.15%
|
1.30
|
| Total Expenses |
|
285.60
+31.69%
|
216.87
+133.19%
|
93.00
+202.68%
|
30.73
|
| Operating Income |
|
-285.60
-31.69%
|
-216.87
-133.19%
|
-93.00
-202.68%
|
-30.73
|
| Total Operating Income As Reported |
|
-285.60
-31.69%
|
-216.87
-133.19%
|
-93.00
-202.68%
|
-30.73
|
| EBITDA |
|
-284.18
-31.15%
|
-216.68
-132.98%
|
-93.00
-203.58%
|
-30.64
|
| Normalized EBITDA |
|
-284.18
-31.15%
|
-216.68
-132.98%
|
-93.00
-203.58%
|
-30.64
|
| Reconciled Depreciation |
|
1.42
+650.26%
|
0.19
|
0.00
|
—
|
| EBIT |
|
-285.60
-31.69%
|
-216.87
-133.19%
|
-93.00
-203.58%
|
-30.64
|
| Net Income |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Pretax Income |
|
-255.56
-40.32%
|
-182.13
-116.86%
|
-83.98
-111.10%
|
-39.78
|
| Net Non Operating Interest Income Expense |
|
30.03
-13.56%
|
34.74
+285.25%
|
9.02
+199.56%
|
-9.06
|
| Interest Expense Non Operating |
|
—
|
—
|
0.00
-100.00%
|
9.15
|
| Net Interest Income |
|
30.03
-13.56%
|
34.74
+285.25%
|
9.02
+199.56%
|
-9.06
|
| Interest Expense |
|
—
|
—
|
0.00
-100.00%
|
9.15
|
| Interest Income Non Operating |
|
30.03
-13.56%
|
34.74
+285.25%
|
9.02
+9702.17%
|
0.09
|
| Interest Income |
|
30.03
-13.56%
|
34.74
+285.25%
|
9.02
+9702.17%
|
0.09
|
| Tax Provision |
|
0.28
+1444.44%
|
0.02
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Net Income From Continuing Operation Net Minority Interest |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Net Income From Continuing And Discontinued Operation |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Net Income Continuous Operations |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Normalized Income |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Net Income Common Stockholders |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Diluted EPS |
|
—
|
-3.30
+1.79%
|
-3.36
-130.11%
|
-1.46
|
| Basic EPS |
|
—
|
-3.30
+1.79%
|
-3.36
-130.11%
|
-1.46
|
| Basic Average Shares |
|
—
|
55.19
+120.72%
|
25.01
-8.22%
|
27.25
|
| Diluted Average Shares |
|
—
|
55.19
+120.72%
|
25.01
-8.22%
|
27.25
|
| Diluted NI Availto Com Stockholders |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Depreciation Amortization Depletion Income Statement |
|
1.13
|
0.00
|
—
|
—
|
| Depreciation And Amortization In Income Statement |
|
1.13
|
0.00
|
—
|
—
|
| Depreciation Income Statement |
|
1.13
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
937.13
+24.30%
|
753.95
+87.83%
|
401.40
+163.99%
|
152.06
|
| Current Assets |
|
741.36
+39.95%
|
529.71
+32.96%
|
398.41
+162.02%
|
152.06
|
| Cash Cash Equivalents And Short Term Investments |
|
730.19
+40.25%
|
520.65
+31.66%
|
395.46
+160.36%
|
151.89
|
| Cash And Cash Equivalents |
|
131.55
-7.22%
|
141.79
+19.84%
|
118.32
-22.10%
|
151.89
|
| Cash Financial |
|
—
|
—
|
—
|
151.89
|
| Other Short Term Investments |
|
598.64
+58.01%
|
378.86
+36.70%
|
277.14
|
0.00
|
| Receivables |
|
5.96
+26.91%
|
4.70
+286.90%
|
1.21
|
—
|
| Accrued Interest Receivable |
|
5.96
+26.91%
|
4.70
+286.90%
|
1.21
|
—
|
| Prepaid Assets |
|
4.60
+75.51%
|
2.62
+50.98%
|
1.74
+1507.41%
|
0.11
|
| Other Current Assets |
|
0.60
-65.27%
|
1.74
+43.49%
|
1.21
+2029.82%
|
0.06
|
| Total Non Current Assets |
|
195.78
-12.69%
|
224.24
+7387.08%
|
3.00
|
0.00
|
| Net PPE |
|
14.38
+7.89%
|
13.32
+413.65%
|
2.59
|
0.00
|
| Gross PPE |
|
15.98
+18.28%
|
13.51
+420.93%
|
2.59
|
0.00
|
| Accumulated Depreciation |
|
-1.61
-750.79%
|
-0.19
|
0.00
|
—
|
| Properties |
|
0.00
|
0.00
|
0.00
|
—
|
| Machinery Furniture Equipment |
|
2.75
|
0.00
|
—
|
—
|
| Other Properties |
|
10.16
-19.72%
|
12.65
+387.66%
|
2.59
|
—
|
| Leases |
|
3.08
+256.32%
|
0.86
|
0.00
|
—
|
| Investments And Advances |
|
172.73
-17.91%
|
210.42
|
0.00
|
—
|
| Other Non Current Assets |
|
8.67
+1641.16%
|
0.50
+24.19%
|
0.40
|
—
|
| Total Liabilities Net Minority Interest |
|
33.25
-10.51%
|
37.16
+72.90%
|
21.49
+115.34%
|
9.98
|
| Current Liabilities |
|
27.91
-2.29%
|
28.56
+38.92%
|
20.56
+105.99%
|
9.98
|
| Payables And Accrued Expenses |
|
20.74
-11.47%
|
23.43
+21.47%
|
19.29
+103.80%
|
9.46
|
| Payables |
|
1.22
+14.01%
|
1.07
-50.02%
|
2.14
+412.68%
|
0.42
|
| Accounts Payable |
|
1.22
+14.01%
|
1.07
-50.02%
|
2.14
+412.68%
|
0.42
|
| Current Accrued Expenses |
|
19.52
-12.69%
|
22.36
+30.40%
|
17.15
+89.53%
|
9.05
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.66
+93.03%
|
1.90
+1034.73%
|
0.17
-67.57%
|
0.52
|
| Current Debt And Capital Lease Obligation |
|
3.50
+8.35%
|
3.23
+193.73%
|
1.10
|
—
|
| Current Capital Lease Obligation |
|
3.50
+8.35%
|
3.23
+193.73%
|
1.10
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
5.34
-37.83%
|
8.60
+821.44%
|
0.93
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
5.34
-37.83%
|
8.60
+821.44%
|
0.93
|
0.00
|
| Long Term Capital Lease Obligation |
|
5.34
-37.83%
|
8.60
+821.44%
|
0.93
|
0.00
|
| Stockholders Equity |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
|
0.00
|
| Common Stock Equity |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
|
0.00
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
—
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
68.40
+15.00%
|
59.48
+22.59%
|
48.52
+1.04%
|
48.02
|
| Ordinary Shares Number |
|
68.40
+15.00%
|
59.48
+22.59%
|
48.52
+1.04%
|
48.02
|
| Additional Paid In Capital |
|
1,464.56
+43.33%
|
1,021.79
+103.00%
|
503.35
|
0.00
|
| Retained Earnings |
|
-561.76
-83.63%
|
-305.92
-147.16%
|
-123.77
-211.10%
|
-39.78
|
| Gains Losses Not Affecting Retained Earnings |
|
1.08
+18.03%
|
0.92
+178.12%
|
0.33
|
0.00
|
| Other Equity Adjustments |
|
1.08
+18.03%
|
0.92
+178.12%
|
0.33
|
—
|
| Total Equity Gross Minority Interest |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
+167.40%
|
142.07
|
| Total Capitalization |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
+167.40%
|
142.07
|
| Working Capital |
|
713.45
+42.36%
|
501.15
+32.63%
|
377.85
+165.95%
|
142.07
|
| Invested Capital |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
|
0.00
|
| Total Debt |
|
8.85
-25.20%
|
11.83
+481.66%
|
2.03
|
0.00
|
| Capital Lease Obligations |
|
8.85
-25.20%
|
11.83
+481.66%
|
2.03
|
0.00
|
| Net Tangible Assets |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
|
0.00
|
| Tangible Book Value |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
|
0.00
|
| Available For Sale Securities |
|
172.73
-17.91%
|
210.42
|
—
|
—
|
| General Partnership Capital |
|
—
|
—
|
—
|
2.14
|
| Investmentin Financial Assets |
|
172.73
-17.91%
|
210.42
|
0.00
|
—
|
| Limited Partnership Capital |
|
—
|
0.00
|
0.00
-100.00%
|
181.86
|
| Total Partnership Capital |
|
—
|
-305.00
-147.08%
|
-123.44
-186.88%
|
142.07
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-227.45
-32.88%
|
-171.17
-128.96%
|
-74.76
-355.11%
|
-16.43
|
| Cash Flow From Continuing Operating Activities |
|
-227.45
-32.88%
|
-171.17
-128.96%
|
-74.76
-355.11%
|
-16.43
|
| Net Income From Continuing Operations |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Depreciation Amortization Depletion |
|
1.42
+650.26%
|
0.19
|
0.00
|
—
|
| Depreciation |
|
1.42
+650.26%
|
0.19
|
0.00
|
—
|
| Depreciation And Amortization |
|
1.42
+650.26%
|
0.19
|
0.00
|
—
|
| Other Non Cash Items |
|
3.68
+117.06%
|
1.69
+1847.13%
|
0.09
-99.24%
|
11.40
|
| Stock Based Compensation |
|
46.28
+98.34%
|
23.33
+282.30%
|
6.10
+184.92%
|
2.14
|
| Change In Working Capital |
|
-15.48
-673.13%
|
-2.00
-132.79%
|
6.11
-37.80%
|
9.81
|
| Change In Prepaid Assets |
|
-2.11
+65.36%
|
-6.08
-118.31%
|
-2.79
-1587.88%
|
-0.17
|
| Change In Payables And Accrued Expense |
|
-0.92
-117.70%
|
5.22
-43.67%
|
9.27
-7.14%
|
9.98
|
| Change In Accrued Expense |
|
-1.07
-117.07%
|
6.29
-17.79%
|
7.65
-19.95%
|
9.56
|
| Change In Payable |
|
0.15
+113.99%
|
-1.07
-166.46%
|
1.61
+285.89%
|
0.42
|
| Change In Account Payable |
|
0.15
+113.99%
|
-1.07
-166.46%
|
1.61
+285.89%
|
0.42
|
| Change In Other Current Assets |
|
-8.47
-8628.87%
|
-0.10
+9.35%
|
-0.11
|
0.00
|
| Change In Other Current Liabilities |
|
-3.98
-280.96%
|
-1.04
-287.04%
|
-0.27
|
0.00
|
| Investing Cash Flow |
|
-179.57
+40.23%
|
-300.46
-9.69%
|
-273.91
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-179.57
+40.23%
|
-300.46
-9.69%
|
-273.91
|
0.00
|
| Net PPE Purchase And Sale |
|
-5.15
-346.79%
|
-1.15
-589.82%
|
-0.17
|
0.00
|
| Purchase Of PPE |
|
-5.15
-346.79%
|
-1.15
-589.82%
|
-0.17
|
0.00
|
| Capital Expenditure |
|
-5.15
-346.79%
|
-1.15
-589.82%
|
-0.17
|
—
|
| Net Investment Purchase And Sale |
|
-174.43
+41.72%
|
-299.31
-9.34%
|
-273.74
|
0.00
|
| Purchase Of Investment |
|
-642.30
+1.10%
|
-649.45
-113.82%
|
-303.74
|
0.00
|
| Sale Of Investment |
|
467.87
+33.62%
|
350.14
+1067.13%
|
30.00
|
0.00
|
| Financing Cash Flow |
|
396.49
-19.92%
|
495.11
+56.98%
|
315.39
+87.38%
|
168.32
|
| Cash Flow From Continuing Financing Activities |
|
396.49
-19.92%
|
495.11
+56.98%
|
315.39
+87.38%
|
168.32
|
| Net Common Stock Issuance |
|
389.63
-21.04%
|
493.48
+56.47%
|
315.39
|
0.00
|
| Proceeds From Stock Option Exercised |
|
6.86
+321.65%
|
1.63
|
0.00
|
—
|
| Changes In Cash |
|
-10.53
-144.88%
|
23.47
+170.53%
|
-33.28
-121.91%
|
151.89
|
| Beginning Cash Position |
|
142.08
+19.79%
|
118.61
-21.91%
|
151.89
|
0.00
|
| End Cash Position |
|
131.55
-7.41%
|
142.08
+19.79%
|
118.61
-21.91%
|
151.89
|
| Free Cash Flow |
|
-232.60
-34.97%
|
-172.33
-129.99%
|
-74.93
-356.13%
|
-16.43
|
| Amortization Of Securities |
|
-7.50
+38.72%
|
-12.24
-298.60%
|
-3.07
|
0.00
|
| Common Stock Issuance |
|
389.63
-21.04%
|
493.48
+56.47%
|
315.39
|
0.00
|
| Issuance Of Capital Stock |
|
389.63
-21.04%
|
493.48
+56.47%
|
315.39
+87.38%
|
168.32
|
| Net Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
168.32
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
168.32
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-20 View
- 42026-04-17 View
- 42026-04-10 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-03-27 View
- 8-K2026-03-25 View
- 8-K2026-03-23 View
- 42026-03-13 View
- 42026-03-06 View
- 42026-03-04 View
- 10-K2026-03-02 View
- 8-K2026-03-02 View
- 42026-02-13 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-01-22 View
- 42026-01-16 View
- 42026-01-09 View
- 42026-01-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|